15 |
Achieving the Superior Treatment Goal for Patients at Risks Through Powerful Inhibition of Two Sources of Cholesterol -"VYTAL Study" |
Szilard Voros |
Nov. 09. 07 |
14 |
Arterial Wall Remodeling in Response to Atheroma Regression with Very Intensive Lipid Lowering |
Matthew Worthley |
Nov. 09. 07 |
13 |
Effects of Statin Therapy on Ruptured Coronay Plaque |
Myeong-Ki Hong |
Nov. 09. 07 |
12 |
Surrogate Markers of CHD & Statins |
Wolfgang Koenig |
Nov. 24. 06 |
11 |
The Cholesterol Balance: The Advanced Approach to Dyslipidemia Management |
Peter Jan Lansberg |
Nov. 24. 06 |
10 |
Inflammation: Novel Target for Cardiovascular Risk Reduction |
Andrew Zalewski |
Sep. 23. 05 |
9 |
Beyond the Statin Therapy: The Importance of HDL Cholesterol |
Ki Hoon Han |
Sep. 23. 05 |
8 |
Early Statin Therapy in Acute Coronary Syndrome |
Cheol Whan Lee |
Sep. 23. 05 |
7 |
The TNT Trial: Is It Time to Shift Our Goals in Clinical Practice |
David Colquhoun |
Sep. 23. 05 |
6 |
Cholesterol Absorption Inhibition: Shaping the Future of Lipid Management |
Ki Hoon Han |
Mar. 11. 05 |